SABS · NASDAQ
SAB Biotherapeutics (SABS) Stock Price & Fundamentals
SAB Biotherapeutics (SABS) closed at $394.30 on Oct 9, 2026, down 0.26% from the previous close of $395.32.
Share price, past year
1Y −9.92%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $394.30 |
| Sep 30, 2026 | $398.28 |
| Aug 31, 2026 | $413.09 |
| Jul 31, 2026 | $409.21 |
| Jun 30, 2026 | $410.36 |
| May 29, 2026 | $388.97 |
| Apr 30, 2026 | $394.66 |
| Mar 31, 2026 | $400.31 |
| Feb 27, 2026 | $405.34 |
| Jan 30, 2026 | $420.34 |
| Dec 31, 2025 | $430.23 |
| Nov 28, 2025 | $453.44 |
| Oct 31, 2025 | $439.01 |
Key statistics
- Market cap
- $32.92B
- P/E (TTM)
- 1,714.4
- EPS (TTM)
- $0.23
- Revenue (TTM)
- —
- Net income (TTM)
- −$12.78M
- Shares outstanding
- 83.5M
- Dividend yield
- —
- 52-week range
- $385.32 – $455.86
SAB Biotherapeutics's market cap is $32.92B, based on a share price of $394.30 and 83.5M shares outstanding as of Jun 30, 2026.
Financials
SAB Biotherapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
SAB Biotherapeutics reported net income of $13.27M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | $13.27M | — | −$0.79 | −$45.71M |
| FY2024ended Dec 31, 2024 | $1.32M | −40.9% | −$34.11M | −2,579.0% | −$3.68 | −$34.63M |
| FY2023ended Dec 31, 2023 | $2.24M | −90.6% | −$42.19M | −1,884.5% | −$7.64 | −$25.32M |
| FY2022ended Dec 31, 2022 | $23.90M | −60.7% | −$18.74M | −78.4% | −$4.31 | −$25.63M |
| FY2021ended Dec 31, 2021 | $60.88M | +10.2% | −$17.14M | −28.2% | −$6.30 | −$8.96M |
| FY2020ended Dec 31, 2020 | $55.24M | — | $20.12M | 36.4% | $7.40 | −$2.73M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2024ended Jun 30, 2024 | $263.14K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $944.58K | — | — |
| Q4 FY2023ended Dec 31, 2023 | $305.01K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $1.27M | — | — |
| Q2 FY2023ended Jun 30, 2023 | $85.52K | — | — |
| Q1 FY2023ended Mar 31, 2023 | $581.10K | — | — |
| Q4 FY2022ended Dec 31, 2022 | $2.16M | — | — |
| Q3 FY2022ended Sep 30, 2022 | $3.59M | — | — |
Company profile
- Name
- SAB Biotherapeutics, Inc.
- Ticker
- SABS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 777 W 41st St, Suite 401, Miami Beach, FL 33140
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001833214
Recent SEC filings
- Aug 6, 2026
- Jul 7, 2026
- Jun 18, 2026
- May 12, 2026
- May 4, 2026
- Apr 22, 2026
- Mar 19, 2026
- Mar 10, 2026
Frequently asked questions
What is SAB Biotherapeutics's stock price?
SAB Biotherapeutics (SABS) closed at $394.30 on Oct 9, 2026, down 0.26% from the previous close of $395.32.
What is SAB Biotherapeutics's market cap?
SAB Biotherapeutics's market cap is $32.92B, based on a share price of $394.30 and 83.5M shares outstanding as of Jun 30, 2026.
How much revenue does SAB Biotherapeutics make?
SAB Biotherapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
What is SABS's P/E ratio?
SAB Biotherapeutics's price-to-earnings ratio is 1,714.4, based on trailing twelve-month diluted EPS of $0.23.
Does SAB Biotherapeutics pay a dividend?
SAB Biotherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from SAB Biotherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures